Related Experiment Video
Updated: May 9, 2025
14:51
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
3.1K
Integrated Computational and Functional Screening Identifies G9a Inhibitors for SETD2-mutant Leukemia
Ya Zhang1,2,3, Mengfang Xia1,2,3, Zhenyi Yi1,2,3
1China National Center for Bioinformation, Beijing 100101, China.
Genomics, Proteomics & Bioinformatics
|April 29, 2025
Summary
G9a inhibitors show promise for treating SETD2-mutant leukemia by downregulating Myc. This epigenetic therapy reverses gene expression changes and selectively targets cancer cells, offering a new therapeutic strategy.
Area of Science:
- Epigenetics
- Cancer Biology
- Pharmacology
Background:
- SETD2 is a tumor suppressor frequently mutated in acute leukemia, linked to chemotherapy resistance and poor prognosis.
- Targeting epigenetic alterations in SETD2-mutant leukemia is crucial for developing novel therapeutics.
Purpose of the Study:
- To identify potential therapeutics for SETD2-mutant leukemia.
- To investigate the mechanism of action for identified drug candidates.
Main Methods:
- Integrated computational prediction and epigenetic compound library screening.
- RNA-sequencing and chromatin immunoprecipitation sequencing (ChIP-seq) analyses.
- Correlation analysis between computational predictions and phenotypic outcomes.
Main Results:
- G9a inhibitors were identified as promising candidates, selectively inhibiting SETD2-deficient cells.
- G9a inhibition downregulated Myc and Myc-regulated genes in SETD2-mutant leukemia cells.
- G9a inhibition led to upregulation of let-7a-2 microRNA, contributing to MYC suppression.
Conclusions:
- G9a inhibitors represent a potential therapeutic strategy for SETD2-mutant leukemia.
- The MYC signature is a key predictor of drug efficacy in this context.
- This study provides insights into refining drug prediction strategies for epigenetic therapies.
